Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Summary

1:1 active treatment: placebo, blinded trial, evaluating the effect of a 4-week treatment period with topical C-82 on skin expression of two gene biomarker surrogates (THBS1 and COMP) for the modified Rodnan skin score (MRSS). Study subjects will be randomized to apply the active study medication daily for 4 weeks to either the right or left forearm and placebo to the contralateral forearm.

Timeline

Start

2015-06

Primary completion

2016-07

Completion

2016-09

Drugs

Indications